Selecta Biosciences Announces $70 Million Private Placement

Go back to Selecta Biosciences Announces $70 Million Private Placement

AskBio Licenses Rights to Selecta Biosciences' (SELB) ImmTOR Immune Tolerance Platform for Treatment of Pompe Disease

December 19, 2019 8:26 AM EST

Selecta Biosciences, Inc. (NASDAQ: SELB) and Asklepios BioPharmaceutical, Inc. (AskBio), today announced that the companies have entered into a license agreement. Under the terms of... More